Athersys, Inc. (NASDAQ:ATHX) has been assigned a $12.00 price target by investment analysts at Maxim Group in a report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 395.87% from the company’s previous close.
The analysts wrote, “A negative blogger blasted Athersys Multistem with Zombie” like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture.””
A number of other analysts have also recently weighed in on ATHX. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Monday, August 14th. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Athersys currently has an average rating of “Buy” and a consensus target price of $7.17.
Athersys (NASDAQ:ATHX) traded down 8.058% during midday trading on Thursday, reaching $2.225. The company had a trading volume of 2,518,653 shares. The company’s market capitalization is $253.45 million. Athersys has a 52-week low of $1.02 and a 52-week high of $2.63. The company’s 50 day moving average is $2.08 and its 200-day moving average is $1.66.
Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.96 million. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.08) earnings per share. Equities analysts expect that Athersys will post ($0.24) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Athersys, Inc. (ATHX) Given a $12.00 Price Target at Maxim Group” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/09/athersys-inc-athx-given-a-12-00-price-target-at-maxim-group.html.
In related news, insider William Lehmann, Jr. sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.38, for a total value of $35,700.00. Following the completion of the transaction, the insider now owns 527,380 shares of the company’s stock, valued at approximately $1,255,164.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of ATHX. Teachers Advisors LLC boosted its stake in Athersys by 21.9% in the 4th quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 28,178 shares during the period. Wells Fargo & Company MN boosted its stake in Athersys by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares during the period. Bank of New York Mellon Corp boosted its stake in Athersys by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 265,165 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 26,526 shares during the period. Vanguard Group Inc. boosted its stake in Athersys by 19.5% in the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock worth $6,668,000 after purchasing an additional 637,322 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Athersys by 35.2% in the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after purchasing an additional 196,981 shares during the period. 19.08% of the stock is owned by hedge funds and other institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.